Education
About Us
Working with TipRanks
Follow Us
Genelux Corp. (GNLX)
NASDAQ:GNLX
GNLX Stock Chart & Stats
$2.74
-$0.06(-2.24%)
At close: 4:00 PM EST
$2.74
-$0.06(-2.24%)
Day’s Range― - ―
52-Week Range$1.99 - $8.54
Previous CloseN/A
Volume23.79K
Average Volume (3M)156.94K
Market Cap
$114.48M
Enterprise Value$82.64M
Total Cash (Recent Filing)$20.91M
Total Debt (Recent Filing)$1.62M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Apr 06, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding44,718,437
10 Day Avg. Volume178,540
30 Day Avg. Volume156,945
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)2.82
Price to Sales (P/S)9277.96
P/FCF Ratio-3.43
Enterprise Value/Market Cap0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-577.90
Enterprise Value/Ebitda-2.62
Forecast
1Y Price Target
$22.50Price Target Upside721.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Differentiated Delivery And MechanismEvidence that Olvi-Vec can be administered systemically and resensitize tumors to platinum, combined with a vaccinia backbone that promotes broad immune activation, may position the asset as a differentiated oncolytic virus and attract sector interest.
Early Clinical EfficacyInterim systemic Olvi-Vec data showing measurable tumor reductions and a meaningful disease control rate in lung cancer could boost investor confidence if similar responses appear in larger cohorts.
Pivotal Trial ProgressionA pivotal Phase 3 intraperitoneal Olvi-Vec study combining the agent with chemotherapy and Avastin supports a clear regulatory pathway in platinum-resistant ovarian cancer, potentially unlocking significant market opportunity.
Bears Say
Financing And Dilution RiskRecent operating losses and modest cash reserves create funding pressure for ongoing trials and increase the likelihood of future capital raises that could dilute existing shareholders.
Heavily Pretreated Population EfficacyMany trial participants progressed on prior checkpoint inhibitors, which suggests lower expected benefit in heavily pretreated patients and increases the chance of muted overall efficacy outcomes.
Small Sample Sizes RiskVery small patient cohorts and limited follow-up in interim analyses increase statistical uncertainty and raise the risk that observed efficacy and safety signals will not replicate in larger studies.
Genelux Corp. News
GNLX FAQ
What was Genelux Corp.’s price range in the past 12 months?
Genelux Corp. lowest stock price was $1.99 and its highest was $8.54 in the past 12 months.
What is Genelux Corp.’s market cap?
Genelux Corp.’s market cap is $114.48M.
When is Genelux Corp.’s upcoming earnings report date?
Genelux Corp.’s upcoming earnings report date is Apr 06, 2026 which is in 78 days.
How were Genelux Corp.’s earnings last quarter?
Genelux Corp. released its earnings results on Nov 05, 2025. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.213 by $0.003.
Is Genelux Corp. overvalued?
According to Wall Street analysts Genelux Corp.’s price is currently Undervalued.
Does Genelux Corp. pay dividends?
Genelux Corp. does not currently pay dividends.
What is Genelux Corp.’s EPS estimate?
Genelux Corp.’s EPS estimate is -0.22.
How many shares outstanding does Genelux Corp. have?
Genelux Corp. has 44,718,437 shares outstanding.
What happened to Genelux Corp.’s price movement after its last earnings report?
Genelux Corp. reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.213. Following the earnings report the stock price went down -32.398%.
Which hedge fund is a major shareholder of Genelux Corp.?
Currently, no hedge funds are holding shares in GNLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genelux Corp. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.50 (721.17% Upside)
$22.50 (721.17% Upside)
Hedge Fund Trend
Decreased
By 631.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $39.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
136.72%
12-Months-Change
Fundamentals
Return on Equity
-98.72%
Trailing 12-Months
Asset Growth
-28.62%
Trailing 12-Months
Company Description
Genelux Corp.
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
GNLX Stock 12 Month Forecast
Average Price Target
$22.50
▲(721.17% Upside)
Technical Analysis
Coherus Biosciences
―
Fate Therapeutics
―
Tonix Pharma
―
Corbus Pharmaceuticals
―
Forte Biosciences
―
Ownership Overview
14.28% Insiders
4.20% Mutual Funds
9.74% Other Institutional Investors
68.15% Public Companies and
Individual Investors